keyword
MENU ▼
Read by QxMD icon Read
search

Tetrahydrocannabinol

keyword
https://www.readbyqxmd.com/read/28644052/a-little-dab-will-do-ya-in-a-case-report-of-neuro-and-cardiotoxicity-following-use-of-cannabis-concentrates
#1
Shannon S Rickner, Dazhe Cao, Kurt Kleinschmidt, Steven Fleming
CONTEXT: The use of marijuana and cannabis concentrates is increasing, especially following decriminalization in several states. Psychosis and cardiotoxicity have been reported following cannabis use; however, myocardial injury from "dabbing" has not yet been reported. We report a case of hyperthermia, tachycardia, hypertension, severe agitation, neuro-, and cardiotoxicity following the use of "dabs" where there is concomitant confirmatory biological and sample testing. CASE DETAILS: A 17-year-old athletic man developed agitation requiring sedation and intubation for safety, with peak systolic blood pressures in the 190s and hyperthermia (to 102 °F)...
June 23, 2017: Clinical Toxicology
https://www.readbyqxmd.com/read/28644037/lower-risk-cannabis-use-guidelines-a-comprehensive-update-of-evidence-and-recommendations
#2
Benedikt Fischer, Cayley Russell, Pamela Sabioni, Wim van den Brink, Bernard Le Foll, Wayne Hall, Jürgen Rehm, Robin Room
BACKGROUND: Cannabis use is common in North America, especially among young people, and is associated with a risk of various acute and chronic adverse health outcomes. Cannabis control regimes are evolving, for example toward a national legalization policy in Canada, with the aim to improve public health, and thus require evidence-based interventions. As cannabis-related health outcomes may be influenced by behaviors that are modifiable by the user, evidence-based Lower-Risk Cannabis Use Guidelines (LRCUG)-akin to similar guidelines in other health fields-offer a valuable, targeted prevention tool to improve public health outcomes...
June 23, 2017: American Journal of Public Health
https://www.readbyqxmd.com/read/28642081/tetrahydrocannabinol-thc-impairs-encoding-but-not-retrieval-of-verbal-information
#3
Mohini Ranganathan, Rajiv Radhakrishnan, Peter H Addy, Ashley Schnakenberg, Ashley Williams, Michelle Carbuto, Jacqueline Elander, Brian Pittman, R Andrew Sewell, Patrick D Skosnik, Deepak Cyril D'Souza
INTRODUCTION: Cannabis and agonists of the brain cannabinoid receptor (CB1R) produce acute memory impairments in humans. However, the extent to which cannabinoids impair encoding and retrieval in humans has not been established. The objective of this analysis was to determine whether the administration of Δ(9)-Tetrahydrocannabinol (THC), the principal psychoactive constituent of cannabis, impairs encoding and/or retrieval of verbal information. MATERIALS AND METHODS: Healthy subjects were recruited from the community...
June 19, 2017: Progress in Neuro-psychopharmacology & Biological Psychiatry
https://www.readbyqxmd.com/read/28641517/the-case-for-cannabinoid-cb1-receptors-as-a-target-for-bronchodilator-therapy-for-%C3%AE-agonist-resistant-asthma
#4
John Ashton, Robert J Hancox
Although b2-receceptor agonists are powerful bronchodilators and are at the forefront of asthma symptom relief, patients who use them frequently develop partial resistance to them. This can be a particularly serious problem during severe attacks, where high dose b2-agonist treatment is the front line therapy. Alternative bronchodilators are urgently needed. In this article we review the evidence for the bronchodilator effects of the cannabinoid CB1 receptor tetrahydrocannabinol (THC) and suggest that the mechanism of action for these effects are sufficiently independent of the mechanisms of standard bronchodilators to warrant clinical investigation...
June 15, 2017: Current Drug Targets
https://www.readbyqxmd.com/read/28641496/guanfacine-attenuates-adverse-effects-of-dronabinol-thc-on-working-memory-in-adolescent-onset-heavy-cannabis-users-a-pilot-study
#5
David S Mathai, Manuela Holst, Christopher Rodgman, Colin N Haile, Jake Keller, Mariyah Z Hussain, Thomas R Kosten, Thomas F Newton, Christopher D Verrico
The cannabinoid-1 receptor (CB1R) agonist Δ9-tetrahydrocannabinol (THC), the main psychoactive constituent of cannabis, adversely effects working memory performance in humans. The α2A-adrenoceptor (AR) agonist guanfacine improves working memory performance in humans. The authors aimed to determine the effects of short-term (6 days) treatment with guanfacine on adverse cognitive effects produced by THC. Employing a double-blind, placebo-controlled crossover design, the cognitive, subjective, and cardiovascular effects produced by oral THC (20 mg) administration were determined twice in the same cannabis users: once after treatment with placebo and once after treatment with guanfacine (3 mg/day)...
June 23, 2017: Journal of Neuropsychiatry and Clinical Neurosciences
https://www.readbyqxmd.com/read/28641128/expectancy-of-impairment-attenuates-marijuana-induced-risk-taking
#6
Rachel L Gunn, Linda Skalski, Jane Metrik
BACKGROUND: Marijuana use has been associated with increased risk-taking and impulsive behavior. While pharmacologic effects of marijuana can lead to inhibitory impairment, expectancy of potential impairment may result in compensatory behavioral response by decreasing impulsive decisions and risky behaviors. With the increases in marijuana use and related problems, a better understanding of the individual characteristics associated with marijuana intoxication and risky behavior is needed...
June 13, 2017: Drug and Alcohol Dependence
https://www.readbyqxmd.com/read/28640062/an-atmospheric-pressure-ionization-ms-ms-assay-using-online-extraction-for-the-analysis-of-11-cannabinoids-and-metabolites-in-human-plasma-and-urine
#7
Jelena Klawitter, Cristina Sempio, Sophie Mörlein, Erik De Bloois, Jacek Klepacki, Thomas Henthorn, Maureen A Leehey, Edward J Hoffenberg, Kelly Knupp, George S Wang, Christian Hopfer, Greg Kinney, Russell Bowler, Nicholas Foreman, Jeffrey Galinkin, Uwe Christians, Jost Klawitter
BACKGROUND: Although, especially in the United States, there has been a recent surge of legalized cannabis for either recreational or medicinal purposes, surprisingly little is known about clinical dose-response relationships, pharmaco- and toxicodynamic effects of cannabinoids such as Δ9-tetrahydrocannabinol (THC). Even less is known about other active cannabinoids. METHODS: To address this knowledge gap, an online extraction, high-performance liquid chromatography coupled to tandem mass spectrometry (LC-MS/MS) method for simultaneous quantification of 11 cannabinoids and metabolites including THC, 11-hydroxy-Δ9-tetrahydrocannabinol (11OH-THC), 11-nor-Δ9-tetrahydrocannabinol-9-carboxylic acid (THC-COOH), 11-nor-Δ9-tetrahydrocannabinol-9-carboxylic acid glucuronide (THC-C-gluc), cannabinol (CBN), cannabidiol (CBD), cannabigerol (CBG), cannabidivarin (CBDV), Δ9-tetrahydrocannabivarin (THCV), and 11-nor-9-carboxy-Δ9-tetrahydrocannabivarin (THCV-COOH) was developed and validated in human urine and plasma...
June 19, 2017: Therapeutic Drug Monitoring
https://www.readbyqxmd.com/read/28634109/cannabis-associated-psychosis-neural-substrate-and-clinical-impact
#8
REVIEW
R M Murray, A Englund, A Abi-Dargham, D Lewis, M Di Forti, C Davies, M Sherif, P McGuire, C D'Souza
Prospective epidemiological studies have consistently demonstrated that cannabis use is associated with an increased subsequent risk of both psychotic symptoms and schizophrenia-like psychoses. Early onset of use, daily use of high-potency cannabis, and synthetic cannabinoids carry the greatest risk. The risk-increasing effects are not explained by shared genetic predisposition between schizophrenia and cannabis use. Experimental studies in healthy humans show that cannabis and its active ingredient, delta-9-tetrahydrocannabinol (THC), can produce transient, dose-dependent, psychotic symptoms, as well as an array of psychosis-relevant behavioral, cognitive and psychophysiological effects; the psychotogenic effects can be ameliorated by cannabidiol (CBD)...
June 17, 2017: Neuropharmacology
https://www.readbyqxmd.com/read/28631315/a-two-year-study-of-%C3%AE-9-tetrahydrocannabinol-concentrations-in-drivers-part-2-physiological-signs-on-drug-recognition-expert-dre-and-non-dre-examinations
#9
Kari Declues, Shelli Perez, Ariana Figueroa
Whole blood samples were examined for ∆(9) -Tetrahydrocannabinol (THC) over 2 years in drivers suspected of driving under the influence. Part one of the study examined the link between [THC] and performance on field sobriety tests. This portion examined objective signs, eye examinations and physiological indicators; and their relationship to the presence of THC. Several objective signs were excellent indicators of the presence of THC: red eyes (94%), droopy eyelids (85.6%), affected speech (87.6%), tongue coating (96...
June 20, 2017: Journal of Forensic Sciences
https://www.readbyqxmd.com/read/28631194/the-use-of-cannabinoids-in-treating-dementia
#10
REVIEW
Megan Weier, Wayne Hall
PURPOSE OF REVIEW: To review and summarise the current evidence on the safety and efficacy of using cannabinoids to treat behavioural and neuropsychiatric symptoms of dementia. RECENT FINDINGS: Two randomised controlled trials testing a synthetic form of tetrahydrocannabinol have shown that while well tolerated, there was no significant therapeutic effect, based on changes to scores on the neuropsychiatric inventory (NPI). Case reports and open label trials have indicated that there may be some therapeutic benefit of adding synthetic cannabinoids as an adjunctive therapy to reduce agitation, aberrant motor behaviour and nighttime behaviour...
August 2017: Current Neurology and Neuroscience Reports
https://www.readbyqxmd.com/read/28613973/the-association-of-cannabis-use-on-inpatient-psychiatric-hospital-outcomes
#11
Melanie Rylander, Helena R Winston, Haley Medlin, Madelyne Hull, Abraham Nussbaum
BACKGROUND: The associations between cannabis use and psychosis are well documented in numerous studies. There is a need to evaluate the impact of cannabis use on inpatient psychiatric utilization and outcomes. OBJECTIVES: To evaluate the impact of cannabis use on psychiatric hospital outcomes. METHODS: This study was conducted between April 20, 2015 and October 20, 2015. All patients (n = 120) admitted to Denver Health with psychotic symptoms were administered a urine toxicology screening testing for the presence of 11-nor-9-carboxy-Δ(9)-tetrahydrocannabinol (THC-COOH, the active metabolite of cannabis)...
June 14, 2017: American Journal of Drug and Alcohol Abuse
https://www.readbyqxmd.com/read/28611591/metabolism-of-the-endocannabinoid-anandamide-open-questions-after-25-years
#12
REVIEW
Mauro Maccarrone
Cannabis extracts have been used for centuries, but its main active principle ∆(9)-tetrahydrocannabinol (THC) was identified about 50 years ago. Yet, it is only 25 years ago that the first endogenous ligand of the same receptors engaged by the cannabis agents was discovered. This "endocannabinoid (eCB)" was identified as N-arachidonoylethanolamine (or anandamide (AEA)), and was shown to have several receptors, metabolic enzymes and transporters that altogether drive its biological activity. Here I report on the latest advances about AEA metabolism, with the aim of focusing open questions still awaiting an answer for a deeper understanding of AEA activity, and for translating AEA-based drugs into novel therapeutics for human diseases...
2017: Frontiers in Molecular Neuroscience
https://www.readbyqxmd.com/read/28602505/proposal-of-5-methoxy-n-methyl-n-isopropyltryptamine-consumption-biomarkers-through-identification-of-in-vivo-metabolites-from-mice
#13
D Fabregat-Safont, M Barneo-Muñoz, F Martinez-Garcia, J V Sancho, F Hernández, M Ibáñez
New psychoactive substances (NPS) are a new breed of synthetically produced substances designed to mimic the effects of traditional illegal drugs. Synthetic cannabinoids and synthetic cathinones are the two most common groups, which try to mimic the effects of the natural compounds (9)Δ-tetrahydrocannabinol and cathinone, respectively. Similarly, synthetic tryptamines are designer compounds which are based on the compounds psilocin, N,N-dimethyltryptamine and 5-methoxy-N,N-dimethyltryptamine found in some mushrooms...
June 5, 2017: Journal of Chromatography. A
https://www.readbyqxmd.com/read/28599212/dose-related-effects-of-delta-9-thc-on-emotional-responses-to-acute-psychosocial-stress
#14
Emma Childs, Joseph A Lutz, Harriet de Wit
OBJECTIVES: Cannabis smokers often report that they use the drug to relax or to relieve emotional stress. However, few clinical studies have shown evidence of the stress-relieving effects of cannabis or cannabinoid agonists. In this study, we sought to assess the influence of delta-9-tetrahydrocannabinol (THC), a main active ingredient of cannabis, upon emotional responses to an acute psychosocial stressor among healthy young adults. METHODS: Healthy volunteers (N=42) participated in two experimental sessions, one with psychosocial stress (Trier Social Stress Test, TSST) and another with a non-stressful task, after receiving 0 (N=13), 7...
May 30, 2017: Drug and Alcohol Dependence
https://www.readbyqxmd.com/read/28592614/the-cannabinoid-cb2-agonist-gw405833-suppresses-inflammatory-and-neuropathic-pain-through-a-cb1-mechanism-that-is-independent-of-cb2-receptors-in-mice
#15
Ai-Ling Li, Lawrence M Carey, Ken Mackie, Andrea G Hohmann
GW405833, widely accepted as a cannabinoid CB2 agonist, suppresses pathological pain in preclinical models without unwanted central side effects of CB1 agonists. However, recent in vitro studies suggest that GW405833 may also behave as a non-competitive CB1 antagonist, suggesting that its pharmacology is more complex than initially appreciated. Here, we further investigated the pharmacological specificity of in vivo antinociceptive actions of GW405833 in models of neuropathic (i.e. partial sciatic nerve ligation (PSNL) model) and inflammatory (i...
June 7, 2017: Journal of Pharmacology and Experimental Therapeutics
https://www.readbyqxmd.com/read/28590798/beyond-ketamine-and-phencyclidine-analytically-confirmed-use-of-multiple-novel-arylcyclohexylamines
#16
Stephen Thornton, David Lisbon, Thomas Lin, Roy Gerona
BACKGROUND: Methoxetamine and 3-methoxy-phencyclidine are novel arylcyclohexylamines whose use and clinical toxicity are poorly reported in the medical literature. We report a case of analytically confirmed use of both methoxetamine and 3-methoxy-phencyclidine. CASE REPORT: A 27-year-old male presented 10 hours after insufflating an Internet-obtained powder. He was hypertensive, tachycardic, and demonstrated dissociated affect, a delayed verbal response to questions, ataxia, and vertical nystagmus...
June 7, 2017: Journal of Psychoactive Drugs
https://www.readbyqxmd.com/read/28583800/analysis-of-natural-product-regulation-of-cannabinoid-receptors-in-the-treatment-of-human-disease
#17
REVIEW
S Badal, K N Smith, R Rajnarayanan
The organized tightly regulated signaling relays engaged by the cannabinoid receptors (CBs) and their ligands, G proteins and other effectors, together constitute the endocannabinoid system (ECS). This system governs many biological functions including cell proliferation, regulation of ion transport and neuronal messaging. This review will firstly examine the physiology of the ECS, briefly discussing some anomalies in the relay of the ECS signaling as these are consequently linked to maladies of global concern including neurological disorders, cardiovascular disease and cancer...
June 2, 2017: Pharmacology & Therapeutics
https://www.readbyqxmd.com/read/28582498/microorganism-design-for-heterologous-biosynthesis-of-cannabinoids
#18
Carvalho Ângela, Esben Halkjær Hansen, Oliver Kayser, Simon Carlsen, Felix Stehle
During the last decade the use of medical Cannabis has expanded globally and legislation is getting more liberal in many countries, facilitating the research on cannabinoids. The unique interaction of cannabinoids with the human endocannabinoid system make these compounds an interesting target to be studied as a therapeutic agent for the treatment of several medical conditions. However, currently there are important limitations in the study, production and use of cannabinoids as pharmaceutical drugs. Besides the main constituent tetrahydrocannabinolic acid, the structurally related compound cannabidiol is of high interest as drug candidate...
June 4, 2017: FEMS Yeast Research
https://www.readbyqxmd.com/read/28580227/does-cannabis-composition-matter-differential-effects-of-delta-9-tetrahydrocannabinol-and-cannabidiol-on-human-cognition
#19
REVIEW
Marco Colizzi, Sagnik Bhattacharyya
PURPOSE OF REVIEW: The lack of clarity about the effect of cannabis use on cognition may be attributable to the considerable heterogeneity among studies in terms of cannabis composition. This article selectively reviews studies examining the distinctive effects of cannabinoids on human cognition, particularly those of delta-9-tetrahydrocannabinol (Δ9-THC) and cannabidiol (CBD). RECENT FINDINGS: Research indicates that ∆9-THC administration acutely impairs cognition, particularly memory and emotional processing...
2017: Current Addiction Reports
https://www.readbyqxmd.com/read/28579491/recommendation-to-reconsider-examining-cannabis-subtypes-together-due-to-opposing-effects-on-brain-cognition-and-behavior
#20
Kristine Rømer Thomsen, Mette Buhl Callesen, Sarah W Feldstein Ewing
Cannabis use represents a major public health issue throughout the globe. Yet, we still lack the most fundamental knowledge on long-term effects of cannabis on neural, cognitive, and behavioral function. Part of this stems from how cannabis has been measured historically. To this end, most empirical examinations of cannabis have consolidated all types of cannabis collectively. However, this approach obscures differences in how cannabinoids operate. In this commentary, we address the contrasting properties of tetrahydrocannabinol (THC) and cannabidiol (CBD) and their opposing effects on cognitive function...
June 1, 2017: Neuroscience and Biobehavioral Reviews
keyword
keyword
8621
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"